Login
$NKTX
$1.21 +$0.00 (0.0%) After hours

$NKTX SEC Filings

Filed On Filing
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an invest...

06 Nov 2026 8-K: Regulation FD Disclosure

SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced ...

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026

10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)

22 Jun 2026 Form 4: Hastings Paul J, Director

Sold 1,776 shares ($4.81K)

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 annual meeting of stockholders (the "Annual Meeting") of Nkarta, Inc. (the "Company") was held on June 10, 2026. The results of the voting at the Annual Meeting are set forth below.

11 Jun 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Behbahani Ali, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: George Simeon, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Vratsanos George, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Scheiner Zachary, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Patterson Leone D, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Dybbs Michael, Director

Granted 37,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Thedinga Angela, Director

Granted 37,000 Stock Option (right to buy)

19 May 2026 SCHEDULE 13D/A
12 May 2026 10-Q
12 May 2026 8-K: Results of Operations and Financial Condition

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2

23 Apr 2026 ARS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support